March 22-24: TBD
TBD
March 30-April 1: Kristen Cavallo, CEO, The Martin Agency
Kristen’s goal with her two kids is to have more stamps in their passports than candles on their birthday cakes. They’ve conquered all seven continents together, including a visit to Antarctica in 2018. And considering she recently returned to be the first female CEO in the 52-year history of The Martin Agency, it’s no big surprise that she’s a fan of going places.
Prior to returning to Martin in December 2017, she helped MullenLowe’s flagship office grow 106% in six years. Since taking the helm at Martin, she has taken key issues head on — eliminated the wage gap, fought invisibility with 34% diversity hires, gotten major buzz for a smattering of clients, and produced double-digit growth with new clients (to include Buffalo Wild Wings, Sling TV, Kohl’s).
But what she’s most proud of is setting an example of resilience and possibility for her children. Whether that’s reflected in summiting Mount Kilimanjaro, crossing the Drake Passage, getting certified to scuba in Egypt’s open water, or just trying something new, she and her family are most comfortable when they’re outside of their comfort zone.
April 20-23: Holly Sullivan, Head of Worldwide Economic Development, Amazon
TBD
April 27-29: Dr. Frank Gupton, Co-Founder, Phlow and CEO, Medicines for All
Dr. Frank Gupton is a professor at Virginia Commonwealth University and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He is the Floyd D. Gottwald Chair of Pharmaceutical Engineering and also serves as Department Chair of the Chemical and Life Science Engineering Department. His thirty-year industrial career centered on the development and commercialization of chemical processes for pharmaceutical applications. Dr. Gupton’s research group is currently focused on the development of continuous processing technology to facilitate the discovery, development and commercialization of drug products. Prior to joining the faculty at Virginia Commonwealth University, Dr. Gupton served as the Executive Director of North American Process Development for Boehringer Ingelheim Pharmaceuticals and led the commercialization of the widely prescribed HIV drug nevirapine. Dr. Gupton received his Bachelors of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University.
Dr. Gupton’s research efforts have focused on streamlining pharmaceutical processes, particularly in the area of active ingredients, by employing the principles of process intensification which include the use of innovative chemistry, novel continuous manufacturing platforms, and new and more efficient catalysts for pharmaceutical applications. The research group’s efforts are guided and driven based on both financial and economic impact that can be derived from this effort. Dr. Gupton is the recipient of the 2018 American Chemical Society Award for Affordable Green Chemistry, and in the same year, he received the Presidential Award for Green Chemistry. In 2019 he received the Peter J. Dunn Award for Green Chemistry and Engineering Impact in the Pharmaceutical Industry from the ACS Green Chemistry Institute Pharmaceutical Round Table. These awards were associated with Professor Gupton’s work on the development of a highly efficient process to produce nevirapine, a first-line treatment in HIV therapy.